Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — 2026 Bloom Burton & Co. Healthcare Investor Conference

23 slides from Satellos Bioscience's conference presentation, April 2026

  1. Slide 1: Corporate Overview

    © 2026 Satellos Bioscience Corporate Overview April 2026 R E G E N E R AT I N G M U S C L E F R O M W I T H I N T M

  2. Slide 2: Legal Disclaimers

    © 2026 Satellos Bioscience Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any The information contained herein is subject to change without statements that express or involve discussions with respect to predictions, expect

  3. Slide 3: Grounded in science. Inspired by need.

    © 2026 Satellos Bioscience Grounded in science. Inspired by need. Our mission is to change the lives of people living with Duchenne muscular dystrophy (DMD) and other muscle diseases by restoring their body’s natural ability to regenerate muscle. CHARLIE, age 8, living with Duchenne 3

  4. Slide 4: Significant market opportunity and value potential in muscle

    © 2026 Satellos Bioscience Significant market opportunity and value potential in muscle Nasdaq Valuation1 Large Therapeutic Need in DMD Company Ticker $US Fatal genetic disease with no cure SRPT $2.3BN  Ongoing loss of muscle mass / function WVE $1.4BN 12,000 individuals in USA and Canada  Affects

  5. Slide 5: Satellos: Rewriting the Duchenne Story

    © 2026 Satellos Bioscience Satellos: Rewriting the Duchenne Story Infants 2 to 4 years 5 to 9 years 10 to 12 years 13 to 19 years 20 years + Children make muscle & Muscle loss > Muscle mass continuously disappears until physical it’s functional muscle gains movement lost, cardiorespiratory failure o

  6. Slide 6: Making Muscle Regeneration Happen with SAT-3247

    © 2026 Satellos Bioscience Making Muscle Regeneration Happen with SAT-3247 SAT-3247 is different Clear Clinical Path Demonstrated Effects  Oral, daily tablet  Concurrent Phase 2 trials underway  On muscle regeneration in canine in children and adults model of DMD following SAT-3247  Safe and tol

  7. Slide 7: Overview of Data

    © 2026 Satellos Bioscience Overview of Data

  8. Slide 8: SAT-3247 Treatment Regenerates Muscle in Canine Model of DMD

    © 2026 Satellos Bioscience SAT-3247 Treatment Regenerates Muscle in Canine Model of DMD Pre-Treatment: Dying Tissue Post: Regenerating Tissue Healthy Comparator 500um 500um  Hind leg biopsy | Study Canine with DMD  Hind leg biopsy | Study Canine with DMD  Hind leg biopsy | Age matched healthy can

  9. Slide 9: SAT-3247 Demonstrated Safety and Target PK in Ph 1a Clinical Trial

    © 2026 Satellos Bioscience SAT-3247 Demonstrated Safety and Target PK in Ph 1a Clinical Trial Adverse Event SAD MAD Category (n=40) (n=32) Dose proportional PK Any TEAE 9 18 Any related TEAE 1a 2b Any serious TEAE 0 0 Any related serious 0 0 TEAE Any TEAE leading to 0 1c withdrawal Any TEAE leading

  10. Slide 10: SAT-3247 Demonstrated Biological Activity in Muscle of DMD adults

    © 2026 Satellos Bioscience SAT-3247 Demonstrated Biological Activity in Muscle of DMD adults Established Markers of DMD AK1 CA3 ENO3 MB ANKRD2 Abbreviations: AK1= adenylate kinase isoenzyme; CA3 = carbonic anhydrase; ENO3 = beta-enolase; MB = myoglobin; ANKRD2 = ankryn repeat domain-containing prote

  11. Slide 11: SAT-3247 Demonstrated Significant Grip Strength Gains in Ph 1b

    © 2026 Satellos Bioscience SAT-3247 Demonstrated Significant Grip Strength Gains in Ph 1b 118.6% Increase in 97.9% Increase in Grip Strength in Dominant Hands Grip Strength in Non-Dominant Hands Mean change Individual Patients Mean change Individual Patients IMPROVEMENT Grip strength is a potential

  12. Slide 12: Grip Strength Improvements Correlate with Cmax and Muscle Mass Levels

    © 2026 Satellos Bioscience Grip Strength Improvements Correlate with Cmax and Muscle Mass Levels Grip Strength vs Cmax Grip Strength vs Creatinine Dominant hand Change in max grip (kg) Dominant hand Change in max grip (kg) IMPROVEMENT Non-dominant hand Non-dominant hand Cmax - Day 1 Baseline Creatin

  13. Slide 13: Grip Strength Gains Demonstrated in Ph 1b Sustained in TRAILHEAD

    © 2026 Satellos Bioscience Grip Strength Gains Demonstrated in Ph 1b Sustained in TRAILHEAD Handgrip Strength Time off SAT-3247: 205-328 days 2x Gain Ph 1b (n=4) TRAILHEAD (n=4) Q1, 2025 Q1, 2026  The period from first dose in Ph 1b to day 56 in TRAILHEAD ranged from ~11 – 14 months  A 2x gain in

  14. Slide 14: Grip Strength Increases Exceed Results Seen in Natural History

    © 2026 Satellos Bioscience Grip Strength Increases Exceed Results Seen in Natural History DMD Grip Strength Duchenne Naturala Historya natural history SAT-3247 SAT-3247overlay Overlaywith withnatural Naturalhistory History IMPROVEMENT a. Modified from Hogrel 2020  Increases seen in patients after 2

  15. Slide 15: Larger Muscles Assessed in TRAILHEAD Demonstrated Trends to Gains

    © 2026 Satellos Bioscience Larger Muscles Assessed in TRAILHEAD Demonstrated Trends to Gains Elbow Shoulder Flexion Flexion Elbow Shoulder Extension Extension  Strength measured by handheld dynamometry device  Dynamometry represents a potentially approvable endpoint 15

  16. Slide 16: Upcoming milestones

    © 2026 Satellos Bioscience Upcoming milestones Overview of TRAILHEAD and BASECAMP

  17. Slide 17: Schema of Ph 1b and TRAILHEAD Studies in DMD Adults

    © 2026 Satellos Bioscience Schema of Ph 1b and TRAILHEAD Studies in DMD Adults M1 M3 M6 9 M12 First Month Month Month Month Month Dose One Three Six Nine Twelve CL-101 Completed Ph 1b Age 18-40 28-days | Q1/25 N=4 returning for additional 11 Months on SAT-3247 N=5 TRAILHEAD Regulatory and Age 16-25

  18. Slide 18: Overview of BASECAMP Clinical Trial

    © 2026 Satellos Bioscience Overview of BASECAMP Clinical Trial Participants ֍ Ambulatory children with DMD | Ages 7, 8 and 9 | N=51 ֍ Placebo-controlled, double-blind, 12-week study Protocol ֍ 2 dose levels of SAT-3247, administered once-daily on weekdays Summary ֍ Randomized 1:1:1 to 60 mg or 120 m

  19. Slide 19: Summary of Major Elements of BASECAMP Study

    © 2026 Satellos Bioscience Summary of Major Elements of BASECAMP Study Start of First M3 End of End of Screening Dose Month 1 Study Ages 7, 8, 9 N=51 4 – 6 Weeks 4 Weeks 88 weeks Weeks Biopsy MRI NSAA PUL 2.0 Dynamometry Stride (95th centile) Safety and Biomarkers  8 sites operational and ramping w

  20. Slide 20: Inside Satellos

    © 2026 Satellos Bioscience Inside Satellos Future plans and financial matters

  21. Slide 21: BASECAMP and TRAILHEAD Clinical Trial Catalysts

    © 2026 Satellos Bioscience BASECAMP and TRAILHEAD Clinical Trial Catalysts Q1 Q2 Q3 Q4  TRAILHEAD: Update at  TRAILHEAD: Submission to  TRAILHEAD: Progress and  TRAILHEAD: One year data MDA FDA to start in USA potentially data updates readout on Ph 1b patients  BASECAMP: Site initiation &  BAS

  22. Slide 22: Financial Summary

    © 2026 Satellos Bioscience Financial Summary Balance sheet supports activities to execute on upcoming milestones Research Analyst Coverage NASDAQ MSLE TSX MSCL Oppenheimer Kostas Biliouris Leerink Joseph P. Schwartz Q4 2025 cash balance US$27.7M February 2026 Financing US$57.2M* H.C. Wainwright Arth

  23. Slide 23: Reimagine how muscle degeneration is treated.

    Reiniagine how muscle degeneration is treated. Regenerate with small molecule medicines. Realize the next horizon to improve lives. satellos REGENERATING MUSCLE FROM WITHIN™

Satellos Bioscience — 2026 Bloom Burton & Co. Healthcare Investor Conference on 6ix